MK-2214

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MK-2214, covering 2025-08-27 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) [Phase 2]